Skip to main content
PMC home page
Journal of Assisted Reproduction and Genetics logoLink to Journal of Assisted Reproduction and Genetics
. 2001 Apr;18(4):199–206. doi: 10.1023/A:1009476411762

CLINICAL ASSISTED REPRODUCTION: Improvement of IVF Outcome in Poor Responders by Discontinuation of GnRH Analogue During the Gonadotropin Stimulation Phase—A Function of Improved Embryo Quality

Morey Schachter 1, Shevach Friedler 1,2, Arie Raziel 1,2, Devorah Strassburger 1, Orna Bern 2, Raphael Ron-El 1,2
PMCID: PMC3455367  PMID: 11432110

Abstract

Purpose: To assess the efficacy of a protocol involving the discontinuation of the GnRH analogue at the mid-phase of ovarian stimulation for IVF in patients with a previous poor response.

Methods: Prospective case-control evaluation compared with same patient's previous performance. Thirty-six patients enrolled in an IVF program were treated in two consecutive cycles. The first with a standardized protocol utilizing mid-luteal administration of Nafarelin (N) 600 mcg/d continued throughout the stimulation phase with human menopausal gonadotropin (hMG) until follicles of 20 mm were identified by transvaginal ultrasound (Standard group). Patients with a poor response in the Standard cycle were treated in the subsequent cycle with N and hMG initially in a similar manner, then N was stopped after 5 days of hMG stimulation (N-stop group). All clinical and laboratory aspects of treatment were done in a similar fashion in both cycles, each patient acting as her own control.

Results: Results were analyzed by paired t test. The change in each parameter in the N-stop cycle was expressed as the percent change as compared with the standard protocol cycle for each patient. Peak estradiol (E2) and number of aspirated oocytes were increased in the N-stop cycle (+16.9% and +28%, respectively), but insignificantly so. The percent of cleaving embryos was significantly increased by 27.9% (p = 0.03) in the N-stop cycle, as embryo morphology was improved by 22% (p = 0.02). The efficacy of gonadotropin treatment was enhanced in the N-stop cycle, as expressed by a 32.5% increase in oocytes retrieved per hMG ampoule administered (p = 0.04). Three cycles of 36 were cancelled during the N-stop cycle, whereas only one was cancelled in the standard protocol cycle. Of the 36 patients, 7 conceived in the N-stop protocol and 5 are ongoing pregnancies.

Conclusion: Discontinuation of GnRH-a during ovarian stimulation for IVF has a beneficial, but not statistically significant, effect on both E2 and oocyte production. Embryo cleavage rates and morphology were significantly improved, this may be due to improved oocyte quality, which may have been responsible for achieving pregnancies. The efficacy of gonadotropin treatment was enhanced when GnRH-a was discontinued. These results hint that GnRH-a may have a direct negative effect on folliculogenesis and oocytes, which is apparent especially in poor responder patients.

Keywords: Controlled ovarian hyperstimulation (COH), embryo morphology, gonadotropin-releasing-hormone analogue (GnRH-a), in vitro fertilization (IVF), poor responders

Full Text

The Full Text of this article is available as a PDF (78.2 KB).

REFERENCES

  • 1.Hugues JN, Cedrin Dunerin I. Revisiting gonadotropin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins. Hum Reprod Update. 1998;4:83–101. doi: 10.1093/humupd/4.1.83. [DOI] [PubMed] [Google Scholar]
  • 2.Filicori M, Cognigni GE, Arnone R. Role of different GnRH agonist regimens in pituitary suppression and the outcome of controlled ovarian hyperstimulation. Hum Reprod. 1996;11(Suppl.3):123–132. doi: 10.1093/humrep/11.suppl_3.123. [DOI] [PubMed] [Google Scholar]
  • 3.Parinaud J, Beaur A, Bourreau E, Vieitez G, Pontonnier G. Effect of a luteinizing releasing hormone agonist (Buserelin) on steroidogenesis of cultured human preovulatory granulosa cells. Fertil Steril. 1988;50:597–602. doi: 10.1016/s0015-0282(16)60190-5. [DOI] [PubMed] [Google Scholar]
  • 4.Gaetje R. Influence of gonadotropin releasing hormone (GnRH) and a GnRH-agonist on granulosa cell steroidogenesis. Clin Exp Obstet Gynecol. 1994;21:164–169. [PubMed] [Google Scholar]
  • 5.Yang BC, Uemura T, Minaguchi H. Effects of a gonadotropin releasing hormone agonist on oocyte maturation, fertilization and embryonal development in mice. J Assist Reprod Genet. 1995;12:728–732. doi: 10.1007/BF02212901. [DOI] [PubMed] [Google Scholar]
  • 6.Yoshimura Y, Nakamura Y, Ando M, Shikawa S, Koyama N, Nanno T. Direct effect of gonadotropin releasing hormone agonists on the rabbit ovarian follicle. Fertil Steril. 1992;57:1091–1097. doi: 10.1016/s0015-0282(16)55029-8. [DOI] [PubMed] [Google Scholar]
  • 7.Winslow KL, Gordon K, Williams RF, Hodgen GD. Interval required for gonadotropin releasing hormone agonist-induced down regulation of the pituitary in cynomolgus monkeys and the duration of the refractory state. Fertil Steril. 1992;58:1209–1214. doi: 10.1016/s0015-0282(16)55571-x. [DOI] [PubMed] [Google Scholar]
  • 8.Macnamee MC, Howles CM, Edwards RG, Taylor PJ, Elder KT. Short term luteinizing hormone releasing hormone agonist treatment: Prospective trial of a novel ovarian stimulation regimaen for in vitro fertilization. Fertil Steril. 1989;52:264–269. doi: 10.1016/s0015-0282(16)60853-1. [DOI] [PubMed] [Google Scholar]
  • 9.Hazout A, de Ziegler D, Cornel C, Fernandez H, Lelaidier C, Frydman R. Comparison of short 7-day and prolonged treatment with gonadotropin releasing hormone agonist desensitization for controlled ovarian hyperstimulation. Fertil Steril. 1993;59:596–600. doi: 10.1016/s0015-0282(16)55806-3. [DOI] [PubMed] [Google Scholar]
  • 10.Veeck LL. Atlas of the Human Oocyte and Early Conceptus, Vol. 2. Baltimore: Williams and Wilkins; 1991. pp. 427–444. [Google Scholar]
  • 11.Plachot M, Junca AM, Mandelbaum J, Cohen J, Salat-Baroux J, DaLage C. Timing of in vitro fertilization of cumulus free and cumulus enclosedhumanoocytes. Hum Reprod. 1986;1:237–239. doi: 10.1093/oxfordjournals.humrep.a136392. [DOI] [PubMed] [Google Scholar]
  • 12.Hsueh AJ, Jones PB. Extrapituitary actions of gonadotropin-releasing hormone. Endocr Rev. 1981;2:437–461. doi: 10.1210/edrv-2-4-437. [DOI] [PubMed] [Google Scholar]
  • 13.Fraser HM, Bramley TA, Miller WR, Sharpe RM. Extrapituitary actions of LHRH analogues in tissues of the human female and investigation of the existence and function of LHRH-like peptides. Prog Clin Biol Res. 1986;225:29–54. [PubMed] [Google Scholar]
  • 14.Raga F, Casan EM, Bonilla F, Bonilla-Musoles F, Polan ML: Human oviductal gonadotropin releasing hormone: Possible implications in fertilization, early embryonic development and implantation. Fifteenth Annual Meeting of the ESHRE, Tours, France, 1999, Abstract No. 28 [DOI] [PubMed]
  • 15.Minaretzis D, Jakubowski M, Mortola JF, Pavlou S. Gonadotropin releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J Clin Endocrinol Metab. 1995;80:430–434. doi: 10.1210/jcem.80.2.7852501. [DOI] [PubMed] [Google Scholar]
  • 16.Latouche J, Crumeyrolle-arias M, Jordan D. GnRH receptors in human granulosa cells-anatomical localization and chracterisation by autoradiographic study. Endocrinology. 1989;125:1739–1741. doi: 10.1210/endo-125-3-1739. [DOI] [PubMed] [Google Scholar]
  • 17.Brus L, Lambalk CB, de Koning J, Helder MN, Janssens RM, Schoemaker J. Specific gonadotropin releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles. Hum Reprod. 1997;12:769–773. doi: 10.1093/humrep/12.4.769. [DOI] [PubMed] [Google Scholar]
  • 18.Racowsky C, Prather AL, Johnson MK, Overa SP, Gelety TJ. Prematurely condensed chromosomes and meiotic abnormalities in unfertilized human oocytes after ovarian stimulation with and without gonadotropin releasing hormone agonist. Fertil Steril. 1997;67:932–938. doi: 10.1016/s0015-0282(97)81410-0. [DOI] [PubMed] [Google Scholar]
  • 19.Raga F, Casa FM, Kruessel JS, Bonilla F, Bonilla-Musoles F, Polan ML: Gonadotropin releasing hormone modulation of vascular endothelial growth factor and its transmembrane receptors FLT-1, KDR and sFLT-1: Role in early implantation. 15th Meeting of the ESHRE, Tours, France, 1999, Abstract No. 191
  • 20.Imai A, Takagi A, Horibe S, Takagi H, Tamaya T. Evidence for tight coupling of gonadotropin releasing hormone receptor to stimulated FAS ligand expression in reproductive tract tumors: Possible mechanism for hormonal control of apoptotic cell death. J Clin Endocrinol Metab. 1998;83:427–431. doi: 10.1210/jcem.83.2.4530. [DOI] [PubMed] [Google Scholar]
  • 21.Kakar SS. Inhibition of growth and proliferation of EcRG 293 cell line expressing high affinity gonadotropin releasing hormone (GnRH) receptor under the control of an inducible promotor by GnRH agonist (D-Lys-6-GnRH) and antagonist. Cancer Res. 1998;58:4558–4560. [PubMed] [Google Scholar]
  • 22.Ho MN, Delgado CH, Owens GA, Steller MA. Insulin-like growth factor II participates in the biphasic effect of a gonadotropin releasing hormone agonist on ovarian cancer cell growth. Fertil Steril. 1997;67:870–876. doi: 10.1016/s0015-0282(97)81399-4. [DOI] [PubMed] [Google Scholar]
  • 23.Guidice LC, Yuan W: Insulin-like growth factor II (IGF-II) mediates the steroidogenic and growth-promoting actions of follicle-stimulating hormone on human pre-antral follicles cultured in-vitro. 15th Meeting of the ESHRE, Tours, France, 1999, Abstract No. 155 [DOI] [PubMed]
  • 24.Dodson WC, Myers T, Morton PC, Conn PM. Leuprolide acetate: Serum and follicular fluid concentrations and effects on human fertilization, embryo growth and granulosa-lutein cell progesterone accumulation in vitro. Fertil Steril. 1988;50:612–617. doi: 10.1016/s0015-0282(16)60193-0. [DOI] [PubMed] [Google Scholar]
  • 25.Casper R, Erickson G, Yen SCC. Studies on the effect of GnRH and its agonist on human luteal steroido genesis in vitro. Fertil Steril. 1984;42:39–43. doi: 10.1016/s0015-0282(16)47955-0. [DOI] [PubMed] [Google Scholar]
  • 26.Simon A, Benshushan A, Shushan A. A comparison between a standard and reduced dose of DTRP-6-luteinizing hormone administered after pituitary suppression for in vitro fertilization. Hum Reprod. 1994;9:1813–1817. doi: 10.1093/oxfordjournals.humrep.a138340. [DOI] [PubMed] [Google Scholar]
  • 27.Ben Rafael Z, Feldberg D. The poor-responder patient in an in vitro fertilization embryo transfer program. J Assist Reprod Genet. 1993;10:118–120. doi: 10.1007/BF01207732. [DOI] [PubMed] [Google Scholar]
  • 28.Pantos K, Meimeth-Damianaki T, Vaxevanoglu T, Kapetanakis E. Prospective study of a modified gonadotropin-releasing hormone agonist long protocol in an in vitro fertilization program. Fertil Steril. 1994;61:709–713. doi: 10.1016/s0015-0282(16)56650-3. [DOI] [PubMed] [Google Scholar]
  • 29.Sungurtekin U, Jansen RP. Profound luteinizing hormone suppression after stopping the gonadotropin-releasing hormone agonist leuprolide acetate. Feril Steril. 1995;63:663–665. [PubMed] [Google Scholar]
  • 30.Fujii S, Sagara M, Kudo H, Kagiya A, Sato S, Saito Y. A prospective randomized comparison between long and discontinous-long protocols of gonadotropin-releasing hormone agonist for in vitro fertilization. Fertil Steril. 1997;67:1166–1168. doi: 10.1016/s0015-0282(97)81458-6. [DOI] [PubMed] [Google Scholar]
  • 31.Faber BM, Mayer J, Cox B, Jones D, Toner JP, Oehninger S, Muasher SJ. Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders. Fertil Steril. 1998;69:826–830. doi: 10.1016/s0015-0282(98)00040-5. [DOI] [PubMed] [Google Scholar]
  • 32.Damario MA, Moomjy M, Tortoriello D, Moy F, Davis OK, Rosenwaks Z. Delay of gonadotropin stimulation in patients receiving gonadotropin-releasing hormone agonist (GnRH-a) therapy permits increased clinical efficiency and may enhance in vitro fertilization (IVF) pregnancy rates. Fertil Steril. 1997;68:1004–1010. doi: 10.1016/s0015-0282(97)00392-0. [DOI] [PubMed] [Google Scholar]
  • 33.Dirnfeld M, Fruchter O, Yshai D, Lissak A, Ahdut A, Abramovici H. Cessation of gonadotropin-releasing hormone analogue (GnRH-a) upon down regulated versus conventional long GnRH-a protocol in poor responders undergoing in vitro fertilization. Fertil Steril. 1999;72:406–411. doi: 10.1016/s0015-0282(99)00289-7. [DOI] [PubMed] [Google Scholar]
  • 34.Pinkas H, Orvieto R, Avrech OM, Rufas O, Ferber A, Ben-Rafael Z, Fisch B. Gonadotropin stimulation following GnRH-a priming for poor responders in in vitro fertilizationembryo transfer programs. Gynecol Endocrinol. 2000;14:11–14. doi: 10.3109/09513590009167654. [DOI] [PubMed] [Google Scholar]
  • 35.Wheeler CA, Cole BF, Frishman GN, Seifer DB, Lovegreen SB, Hackett RJ. Predicting probabilities of pregnancy and multiple gestation from in vitro fertilization-a new model. Obstet Gynecol. 1998;91:696–700. doi: 10.1016/s0029-7844(98)00008-8. [DOI] [PubMed] [Google Scholar]
  • 36.Hu Y, Maxson WS, Hoffman DI, Ory SJ, Eager S, Dupre J, Lu C. Maximizing pregnancy rates and limiting higher-order multiple conceptions by determining the optimal number of embryos to transfer based on quality. Fertil Steril. 1998;69:650–657. doi: 10.1016/s0015-0282(98)00024-7. [DOI] [PubMed] [Google Scholar]
  • 37.Van Kooij RJ, Looman CW, Habbema JD, Dorland M, te Velde ER. Age dependent decrease in embryo implantation rate after in vitro fertilization. Fertil Steril. 1996;66:769–775. doi: 10.1016/s0015-0282(16)58634-8. [DOI] [PubMed] [Google Scholar]
  • 38.Rosenboom TJ, Vermeiden JPW. Evaluation of embryo scoring systems and their value in predicting in vitro fertilization outcome. Assist Reprod Rev. 1995;5:53–59. [Google Scholar]
  • 39.Smitz J, Van den Abbeel E, Bollen N, Camus M, Devroey P, Tournaye H, Van Stierteghem AC. The effect of gonadotropin releasing hormone (GnRH) agonist in the follicular phase of in vitro fertilization outcome in normo-ovulatory women. Hum Reprod. 1992;7:1098–1102. doi: 10.1093/oxfordjournals.humrep.a137800. [DOI] [PubMed] [Google Scholar]
  • 40.Raga F, Casan EM, Kruessel J. The role of gonadotrophinreleasing hormone in murine preimplantation embryonic development. Endocrinology. 1999;140:3705–3712. doi: 10.1210/endo.140.8.6899. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Assisted Reproduction and Genetics are provided here courtesy of Springer Science+Business Media, LLC

RESOURCES